The EGFR pathway signals through Kras/Braf and although EGFR/c-Erb-B2 amplifications are rare in CRC, gain-of-function mutations in KRAS/BRAF are extremely common and are seen in up to 60% of tumours [12], [13]. Here, KRAS is linked to colorectal carcinoma.